Abstract Background: Critical shortages of organs for transplantation jeopardize many lives. Observational data suggest that better fluid management for deceased organ donors could increase organ recovery. We conducted the first large multicenter randomized trial in brain-dead donors to determine whether protocolized fluid therapy increases the number of organs transplanted. Methods: We randomly assigned donors to either protocolized or usual care in eight organ procurement organizations. A ''protocol-guided fluid therapy'' algorithm targeting the cardiac index, mean arterial pressure and pulse pressure variation was used. Our primary outcome was the number of organs transplanted per donor, and our primary analysis was intention to treat. Secondary analyses included: (1) modified intention to treat where only subjects able to receive the intervention were included and (2) 12-month survival in transplant recipients. The study was stopped early. Results: We enrolled 556 donors: 279 protocolized care and 277 usual care. Groups had similar characteristics at baseline. The study protocol could be implemented in 76 % of subjects randomized to the intervention. There was no significant difference in mean number of organs transplanted per donor: 3.39 organs per donor (95 % CI 3.14-3.63) with protocolized care compared to 3.29 usual care (95 % CI 3.04-3.54; mean difference, 0.1, 95 % CI -0.25 to 0.45; p = 0.56). In modified intention-to-treat analysis the mean number of organs increased (3.52 organs per donor, 95 % CI 3.23-3.8), but not statistically significantly (mean difference, 0.23, 95 % CI -0.15 to 0.61; p = 0.23). Among the 1,430 recipients of organs from study subjects with data available, 56 deaths (7.8 %) occurred in the protocolized care arm and 56 (7.9 %) in
Introduction
Despite efforts to increase organ donation [1] [2] [3] [4] , there remains a critical shortage of both organ donors and organs transplanted per donor [5, 6] . Strategies to increase recovery of organs from donors are therefore urgently needed. Compared to historical controls, donor management with increased attention to fluid resuscitation has been shown to reduce cardiovascular collapse and increase the number of organs transplanted per donor [7] . However, excessive fluid may also cause organ edema. Optimal management of donor hemodynamics, as in the live patient, aims to achieve euvolemia, maintain blood pressure, and attain a cardiac output to achieve gradients of perfusion pressure and blood flow that promote organ function with minimal use of vasoactive drug support. While there are several reasons why not all potential organs are donated and subsequently transplanted, hemodynamic instability of the donor is an important and modifiable factor.
One method to assess fluid optimization is to examine the pulse pressure variation (PPV) while receiving positive pressure mechanical ventilation [8] [9] [10] [11] . We previously reported an association between increased PPV, indicating fluid responsiveness, and increased levels of inflammatory mediators in the donor [12] . Furthermore, increased concentrations of the circulating inflammatory mediator interleukin (IL)-6 in donors was shown to predict 6-month hospital-free survival in recipients [13] . We therefore conducted the first large multicenter randomized trial (MOnIToR) in brain-dead donors to determine whether protocolized fluid therapy would increase organs transplanted and improve survival in the recipients compared to usual care.
Methods
Detailed study methods and statistical analysis plan have been published previously [14] . Abbreviated methods follow. LiDCO Ltd. provided equipment education, training and support. An external advisory committee was assembled and included content experts and an independent statistician. The committee was chaired by an investigator outside of the coordinating center and not affiliated with any participating OPO (RP). The committee reviewed study conduct and the results of the interim analysis and made recommendations to the MOnIToR executive committee. This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system included data on all donors, wait-listed candidates and transplant recipients in the US, submitted by the members of the Organ Procurement and Transplantation Network (OPTN), and has been described elsewhere [15] . The Health Resources and Services Administration (HRSA), US Department of Health and Human Services provides oversight of the activities of the OPTN and SRTR contractors. All the authors vouch for the integrity and the accuracy of the analysis and for the fidelity of the study to the protocol.
Selection of subjects
Subjects were older than 16 years of age, declared brain dead and considered eligible for organ donation. An arterial catheter in place or a plan to place one was also required for enrollment. Donors were excluded from the study when research consent was not granted or there was inability to perform minimally invasive hemodynamic monitoring. Patients receiving lithium therapy; known severe aortic regurgitation, intra-cardiac shunts or on intra-aortic balloon pump; receiving extracorporeal membrane oxygenation or ventricular assist device support were also excluded.
Intervention
After obtaining research consent, entry criteria and other baseline data were entered into a web-based enrollment application. Donors were assigned a study identification number and treatment allocation. Randomization was 1:1 into each arm, achieved using a web-based randomization system. Randomization was stratified according to the donor's age C65 versus \65. In the usual care arm, the donor was managed according to local standards, which did not include functional hemodynamic monitoring. In the protocolized arm, a noninvasive hemodynamic monitor (LiDCO Plus, LiDCO Ltd., London, UK) was connected to the donor's indwelling arterial catheter and calibrated. A protocol guiding fluid therapy ( Fig. 1 ) was followed until transfer to the operating room for organ procurement.
Outcome measures and definitions
The primary outcome measure was the number of organs transplanted per donor. Secondary outcomes included: (1) the number of organs recovered regardless of whether transplanted; (2) the observed (O) versus expected (E) organs transplanted (O/E) ratio; (3) recipient survival to 6 months; (4) 6-month hospital-free survival (6 mHFS) in recipients-defined as recipient survival in days after transplantation in the first 6 months (6 mHFS = days alive up to 180 days after transplantation minus index hospital length of stay in days).
Statistical analysis
Our primary analysis was an intention-to-treat (ITT) analysis of the mean number of organs transplanted per donor in each group with one interim and a final analysis. As described previously [14] , we planned in advance for a modified intention-to-treat (mITT) analysis where only subjects able to receive the intervention were included in the protocolized care arm (excluding donors when devices were unavailable, incompatible with local hospital equipment or technical problems unrelated to the subjects precluded use of the device occurred). In addition, we planned for a 'responder' analysis where donors in the protocol arm were judged to have responded to care by protocol. This determination was made by consensus of three investigators (AA, RM, JAK) based on changes in hemodynamics including PPV and blinded to study outcomes as previously described [14] . Finally, we calculated the observed (O) versus expected (E) organs transplanted (O/E) ratio as previously described [16] . A detailed description of this metric has been reported previously [14, 16] . The study was designed to enroll 960 subjects in order to detect a difference of 0.5 organs per donor assuming a mean of 3.1 organs transplanted per donor. A single interim analysis was conducted after accrual of 50 % of the initially planned subjects (480). Results of the interim analysis were forwarded to the Executive Steering committee, who determined that the trial did not meet the stopping criteria set by the O'Brien-Fleming criterion, and the study was continued until 23 March 2013, when the study resources would be exhausted.
Donor characteristics between the protocolized and usual care groups were compared using Wilcoxon's test for continuous data (e.g., age) and v 2 tests with correction for continuity for categorical variables or its exact version, or the Fisher's test, as appropriate. The primary endpoint of number of organs transplanted was presented using the mean and 95 % Wald confidence intervals separately for the two arms, and the mean difference between the two arms was tested using the two-sample two-sided t test. The secondary endpoints of the number of organs recovered and observed/expected ratio were analyzed using the same statistical methods.
The secondary endpoint, 6-month hospital-free survival (6 mHFS), was analyzed using survival analysis methodology as some recipients were lost to follow-up before 180 days. Kaplan-Meier survival curves were used to visually investigate the differences in the distribution of six mHFS between the two arms, while the log-rank test was used to compare differences between the two arms. A Cox proportional hazard model was used to quantify the hazard ratio, and the results were presented as point estimate and 95 % confidence interval. Overall recipient survival was calculated as the time from transplant to death. Since many of the recipients were censored, the analysis was limited to 12-month follow-up after transplantation. Usual methods of survival analysis, namely, the Kaplan-Meier curves, log-rank test and Cox model, were used respectively to investigate the survival pattern across arms, to test the difference in distribution, and to quantify the hazard ratio. We conducted two preplanned subgroup analyses examining expanded criteria donors (ECD) versus standard criteria and age C65 versus \65 separately.
Sensitivity analyses
Aborted cases (e.g., discovery of metastatic cancer or various infections or serology) are typically excluded from the assessment of the number of organs transplanted from each donor. For all primary and secondary analyses, aborted cases were excluded. However, as a sensitivity analysis we also reran our primary and secondary analyses considering aborted cases as having contributed zero organs.
Provider survey
In order to elucidate the opinions of the bedside coordinators as to relative ease of delivering the intervention, we conducted a brief post-study survey. The survey questions are provided in the supplement (Table S3) .
Results

Study subjects
We enrolled 556 brain-dead organ donors; 279 were randomly assigned to protocolized care and 277 to usual care. Study flow is shown in Fig. 2 ; 48 donors were aborted after randomization by the OPOs per standard protocols (e.g., a donor found to have metastatic cancer). No follow-up data are available on aborted cases. Characteristics of the remaining 508 donors are shown in Table 1 and are well balanced between groups. Protocolized care was associated with increased use of fluids. However, there were no differences in vasoactive medication use between the two groups ( Table 2) .
Number of organs transplanted
The distribution of organs transplanted from each group is shown in Table 3 . We found no significant difference in the mean number of organs transplanted per donor with 3.39 (95 % CI 3.14-3.63) organs per donor in the protocolized care arm compared to 3.29 (3.04-3.54) organs per donor in the usual care arm (mean difference, 0.10, 95 % CI -0.25 to 0.45; p = 0.56). In the mITT analysis the mean number of organs transplanted per donor increased (3.52 organs per donor, 95 % CI 3.23-3.8), but not statistically significantly (mean difference, 0.23, 95 % CI -0.15 to 0.61; p = 0.23). Finally, in the 'responder' analysis the mean number of organs transplanted per donor increased further to 3.87 ± 2.16, bringing the mean difference to 0.58 ± 2.07 (95 % CI -0.02 to 1.19; p = 0.059). These results are illustrated in Fig. 3 .
Preplanned subgroup and sensitivity analyses
The mean number of organs transplanted from standard criteria donors was nearly identical by study arm: 3.92 for protocolized and 3.94 for usual care; p = 0.96. For the ECD group, 1.83 organs were transplanted from protocolized care versus 1.66 for usual care [difference 0.16 (-0.30 to 0.63); p = 0.49]. Only 52 donors were C65 years of age, and the mean number of organs transplanted was 1.0 for both study groups. We performed sensitivity analyses repeating ITT and mITT analysis where aborted cases were considered to have contributed zero organs (rather than being excluded). The results were very similar to the analysis presented above (data not shown).
Recipient outcomes
Among the 1,476 recipients (740 in protocolized care and 736 in usual care) of organs from study subjects for whom data were available from SRTR, 1,430 (718 in protocolized care and 712 in usual care) had survival data available. Of these, within the first 12 months of transplantation, 56 deaths (7.8 %) occurred in the protocolized care arm and 56 (7.9 %) in the usual care arm [hazard ratio: 0.97 (0.66-1.42), p = 0.86]. Survival curves for recipients of organs from donors in the ITT and mITT cohorts are shown in Figure S2 . No statistically significant differences were observed between treatment arms in either group.
Finally, the distribution of 6-month hospital-free survival was almost identical between recipients of organs from protocolized and usual care donors with a median (25th percentile, 75th percentile) of 171 (164-175) versus 171 (163-174) days (p = 0.35).
Post-study provider survey
Results of our survey are provided in the supplement (Table  S3) . Notably, while more than 50 % of procurement coordinators found the protocol easy to follow, none (0 %) classified the hemodynamic monitor device as 'easy' to use. While the protocol was implemented in 76 % of subjects randomized to the intervention, only about a third of coordinators reported strictly adhering to the protocol.
Discussion
MOnIToR is the only large multicenter randomized controlled trial of organ donor management published to date. Our results demonstrate that protocolized fluid therapy is not superior to usual care whether considering a strict ITT or a modified ITT analysis. Although these results are disappointing, several important findings should be noted. First, large-scale, multicenter, pragmatic trials have not been the norm in donor management. Prior studies have generally been small and single-center investigations [7, 17, 18] , and outcomes have often been limited to short-term organ functional assessments. This has led to adoption of clinical practices based on low-level evidence. For example, thyroid hormone has been commonly used in organ donors based on small case series. A recent metaanalysis of four existing RCTs (n = 209) showed no benefit [19] . Similar results have been reported with corticosteroids [20] . Other trials have focused on specific organs. Mascia and colleagues randomized 118 potential lung donors across 12 centers to a lung protective ventilation strategy and reported a doubling (from 27 to 54 %) of the number of organs transplanted without impacting 6-month recipient survival [21] . Lowtidal volume ventilation was not standard for donors in our [22] . Our study demonstrates that large pragmatic trials are feasible in donors-using sample sizes necessary for detecting realistic effect sizes.
Second, though our study demonstrates feasibility, complex interventions that rely on skilled operators or, as in our study, availability and functionality of equipment, are less well suited to this area of medicine [23] [24] [25] [26] . Organ procurement coordinators have difficult jobs caring for donors at different institutions with different types of cardiac monitors and different cultures.
Third, as to the effect of the intervention itself, the effect size, if there is any, is likely to be smaller than hypothesized. The mITT analysis likely reflects the ''best case scenario'' and showed a point estimate for difference [27] [28] [29] are being studied. However, given the magnitude of the problem and the potential for benefit, new interventions are needed. Our protocolized fluid therapy was provided on a background of routine hemodynamic management. Prior to our study and to date, there is no consensus regarding the use of inotropes in the management of donors and therefore it was not possible to protocolize this aspect of care. Our study protocol focused on fluids and vasopressors and left inotropes and other agents at the discretion of the clinicians managing the donor. However, our analysis of protocol ''responders'' suggests that efforts to improve donor hemodynamics are likely worthwhile. Indeed, responders nearly achieved a significant improvement in the number of organs used, and the point estimate was greater than the originally hypothesized difference of 0.5 organs. Unfortunately, less than a third of donors (29 %) randomized to the intervention met our criteria for response, suggesting that either more effective interventions are needed or that some donors do not have modifiable hemodynamics.
We faced several challenges conducting the study; some were expected and have been reported previously [30] [31] [32] . Our study highlights the fact that complex interventions are challenging and perhaps simpler interventions could prove to be more effective in achieving goals of donor care. Despite the extensive training we provided, some coordinators had difficulties with LiDCO calibration and many felt that it was time consuming. In our post-study survey, it was clear that none of the providers felt that the intervention was easy, and more than 40 % classified it as hard. Indeed, only 76 % of donors randomized to the intervention were able to receive it because of logistical problems including cable incompatibility, calibration problems or simply the lack of equipment on site. Although most found the protocol itself easy to follow, a simpler monitor system might have facilitated delivery of the intervention.
Unfortunately, it will take several years before new treatments can be developed and new trials can be conducted. While we await these developments, we continue to be faced with an ever-increasing demand for organs and an evergrowing number of potential recipients dying for lack of these organs. For those practitioners using protocol-guided fluid t 506 = 0.58, p = 0.56 Fig. 3 Results of primary and secondary analyses. Shown are differences in mean number of organs transplanted (top) and differences in the ratio of observed versus predicted organs per donor (bottom). Positive difference favors the protocolized arm; nP and nU are the sample sizes in the protocolized and usual care arms, respectively. ITT intention to treat; mITT modified intention to treat therapy, it is reassuring that our intervention did not appear to reduce organs in any subgroup or secondary analysis. Neither were any differences seen in major recipient outcomes such as length of hospitalization or 1-year survival. This suggests that recipients of organs taken from protocolized care donors fared as well as those receiving organs from usual care and that the extra 0.1 organs ''rescued'' by the intervention (or 0.3 in the mITT analysis) did not result in lower quality of organs transplanted. Indeed, it is notable that in subgroup analysis, extended-criteria donors accounted for all the effects seen in the ITT analysis where again a smaller absolute, but similar relative (about 10 %), increase was observed but failed to reach significance.
In conclusion, compared to usual care, protocolized fluid therapy on a background of routine hemodynamic management did not increase the number of organs transplanted from brain-dead organ donors. More effective (and perhaps easier to implement) strategies are needed. Our trial demonstrates the feasibility of studying such interventions using a network of OPOs.
